One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal ...
Expert Rev Clin Pharmacol. 2012;5(3):319-336. Finally, a recent study suggested that although prasugrel significantly reduces thrombotic events in patients with ACS undergoing PCI because of its ...